No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 13 | 15 | 15 | 15 | 15 | 17 | N/A | N/A |
| Operating profit | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | €m | -3 | -4 | -5 | -4 | -5 | -7 | N/A | N/A |
| EPS reported | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Optomed Oyj, established in 2004 and headquartered in Oulu, Finland, is a medical technology company specializing in the development, production, and sale of portable devices for retinal examination and advanced screening software. The company operates globally, with a presence in Finland and China, structured into dedicated Devices and Software segments. Its Device division focuses on fundus cameras, serving a broad spectrum of medical specialists, including ophthalmologists, pediatricians, endocrinologists, neurologists, and general practitioners. These camera products are marketed under Optomed's own brand names such as Optomed Smartscope Pro, Aurora, Polaris, and Halo, and are also provided as OEM products under labels including Pictor Plus, Pictor Prestige, Visuscout 100, Fundus Module 300, and Signal. The Software segment offers a comprehensive suite of solutions. For eye health, this includes Avenue Eye Screen for managing the workflow of eye disease screening and monitoring (like diabetic retinopathy), Avenue Archive for healthcare data storage and transmission, Avenue Telemedicine for remote image analysis, Avenue AI for automated diabetic retinopathy screening, and Avenue Sync for seamless integration of fundus cameras with hospital systems. Beyond eye care, Optomed provides Avenue Cancer Screen for managing breast, cervical, and colorectal cancer screenings; Optomed RIS for optimizing diagnostic processes in healthcare imaging units; Sectra PACS, a scalable system for high-volume healthcare providers; Optomed Service Portal for supporting imaging service operations; Facad for visible light imaging and cephalometric tracing; and Sectra PACS Pathology, a digital solution for the distribution and diagnosis of scanned glass slides. Furthermore, Optomed extends professional IT consulting services to government bodies. The company's products and solutions are distributed through OEMs, authorized distributors, and its direct sales channels. Its primary clientele includes hospitals, specialized eye clinics, and both independent and chain optician stores.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Optomed Oyj, established in 2004 and headquartered in Oulu, Finland, is a medical technology company specializing in the development, production, and sale of portable devices for retinal examination and advanced screening software. The company operates globally, with a presence in Finland and China, structured into dedicated Devices and Software segments. Its Device division focuses on fundus cameras, serving a broad spectrum of medical specialists, including ophthalmologists, pediatricians, endocrinologists, neurologists, and general practitioners. These camera products are marketed under Optomed's own brand names such as Optomed Smartscope Pro, Aurora, Polaris, and Halo, and are also provided as OEM products under labels including Pictor Plus, Pictor Prestige, Visuscout 100, Fundus Module 300, and Signal. The Software segment offers a comprehensive suite of solutions. For eye health, this includes Avenue Eye Screen for managing the workflow of eye disease screening and monitoring (like diabetic retinopathy), Avenue Archive for healthcare data storage and transmission, Avenue Telemedicine for remote image analysis, Avenue AI for automated diabetic retinopathy screening, and Avenue Sync for seamless integration of fundus cameras with hospital systems. Beyond eye care, Optomed provides Avenue Cancer Screen for managing breast, cervical, and colorectal cancer screenings; Optomed RIS for optimizing diagnostic processes in healthcare imaging units; Sectra PACS, a scalable system for high-volume healthcare providers; Optomed Service Portal for supporting imaging service operations; Facad for visible light imaging and cephalometric tracing; and Sectra PACS Pathology, a digital solution for the distribution and diagnosis of scanned glass slides. Furthermore, Optomed extends professional IT consulting services to government bodies. The company's products and solutions are distributed through OEMs, authorized distributors, and its direct sales channels. Its primary clientele includes hospitals, specialized eye clinics, and both independent and chain optician stores.